C
Carol Sawka
Researcher at University of Toronto
Publications - 84
Citations - 7890
Carol Sawka is an academic researcher from University of Toronto. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 36, co-authored 83 publications receiving 7083 citations. Previous affiliations of Carol Sawka include Cancer Care Ontario & Women's College, Kolkata.
Papers
More filters
Journal ArticleDOI
The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer. British Columbia/Ontario Working Group.
TL;DR: It is concluded that population-based treatment guidelines can play a role in promoting consistent patterns of adjuvant therapy for women with node-negative breast cancer.
Journal ArticleDOI
Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve week chemotherapy program.
TL;DR: A novel 12 week chemotherapy program for HIV-seropositive patients with intermediate grade or small non-cleaved cell NHL resulted in response rates similar to other reports with acceptable toxicity and a very low incidence of PCP.
Journal ArticleDOI
A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancer.
Judy-Anne W. Chapman,Maureen E. Trudeau,Kathleen I. Pritchard,Carol Sawka,B.G. Mobbs,Wedad Hanna,Harriette J. Kahn,David R. McCready,Lavina Lickley +8 more
TL;DR: There was evidence of marked departures from the proportional hazards assumption with two prognostic factors, number of positive nodes and adjuvant systemic therapy, and the data strongly supported the log normal model.
Journal ArticleDOI
Access to Cancer Drugs in Canada: Looking Beyond Coverage Decisions
Roger Chafe,Anthony J. Culyer,Mark J. Dobrow,Peter C. Coyte,Carol Sawka,Susan E. O'Reilly,Kara Laing,Maureen E. Trudeau,Sharon Smith,Jeffrey S Hoch,Steve Morgan,Stuart Peacock,Rick Abbott,Terrence Sullivan +13 more
TL;DR: The study demonstrates the existence of interprovincial variation in publicly funded access to cancer drugs even after these drugs have been approved for public coverage.
Journal ArticleDOI
Improving the quality of lung cancer care in Ontario: the lung cancer disease pathway initiative.
TL;DR: The process by which the CCO lung cancer (LC) DPM was initiated and some of its early successes are described, including the proportion of LC patients, whose symptoms are assessed at least once a month, using a standardized symptom assessment instrument, has improved through the DPM.